HCP Live
Contagion LiveCGT LiveNeurology LiveHCP LiveOncology LiveContemporary PediatricsContemporary OBGYNEndocrinology NetworkPractical CardiologyRheumatology Netowrk

DMARDs Reduce Diabetes Risk in RA and Psoriasis

The Journal of Musculoskeletal Medicine, The Journal of Musculoskeletal Medicine Vol 28 No 8, Volume 28, Issue 8

In patients who have rheumatoid arthritis (RA) or psoriasis, there is a reduced risk of diabetes mellitus (DM) with the use of a tumor necrosis factor α (TNF-α)inhibitor or hydroxychloroquine (HCQ), but not with methotrexate (MTX), compared with other nonbiologic disease-modifying antirheumatic drugs (DMARDs). Evidence suggests a possible role for DMARDs and immunosuppression in DM prevention

In patients who have rheumatoid arthritis (RA) or psoriasis, there is a reduced risk of diabetes mellitus (DM) with the use of a tumor necrosis factor α (TNF-α) inhibitor or hydroxychloroquine (HCQ), but not with methotrexate (MTX), compared with other nonbiologic disease-modifying antirheumatic drugs (DMARDs). Evidence suggests a possible role for DMARDs and immunosuppression in DM prevention.

Solomon and associates conducted a cohort analysis of 121,280 patients with a diagnosis of RA or psoriasis on at least 2 visits. Drug regimens were categorized as 1 of 4 groups: (1) TNF-α inhibitors with or without other DMARDs; (2) MTX without TNF-α inhibitors or HCQ; (3) HCQ without TNF-α inhibitors or MTX; or (4) other nonbiologic DMARDs without TNF-α inhibitors, MTX, or HCQ.

The investigators found 267 newly diagnosed cases of DM (nonbiologic DMARD users, 55; TNF-α inhibitor users, 80; MTX users, 82; and HCQ users, 50). The multivariate adjusted hazard ratios for DM were 0.62, 0.77, and 0.54 for TNF-α inhibitors, MTX, and HCQ, respectively, compared with other nonbiologic DMARDs.

The authors noted that a randomized controlled trial testing the ability of these agents to prevent DM among participants who have a systemic inflammatory disorder should be considered.